Thirty-three randomized controlled trials were identified evaluating 15,971 participants (9,103 (57%) female). 5 key findings →
Participants: 15,971 Evidence: high
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
Thirty-three randomized controlled trials were identified evaluating 15,971 participants (9,103 (57%) female). 5 key findings →
Participants: 15,971 Evidence: high
Full summary, score breakdown and related studies → Original source
The study included 524,975 older adults with dementia who were incident users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%). 5 key findings →
Design: cohort study Participants: 524,975 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Use of donepezil by AD patients resulted in significant delays in NHP. 2 key findings →
Design: open-label trial Participants: 1,115 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We were unable to detect a difference in HRQOL for screening for ADRD among older adults. 3 key findings →
Design: randomized controlled trial Participants: 2,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The techniques evaluated were person-centered showering and the towel bath (a person-centered, in-bed bag-bath with no-rinse soap). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Regular, long-term, customized HE improved the executive function of community-dwelling older people with memory disorders, but the effects were mild and were not observed in other domains of cognition. 3 key findings →
Participants: 210 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Median (IQR) eGFR was 73(60-84) mL/min/1.73 m 2 . 3 key findings →
Design: longitudinal study Participants: 1,334 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Twenty-four-week, randomized, multicenter, parallel-group, double-blind, placebo-controlled trial. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
An exhaustive review of the literature involving 142 studies demonstrated that cognitive enhancers in general have minimal effects on cognition according to minimal clinically important difference and global ratings. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In community-dwelling older persons, the combination of a long-term lifestyle MI and omega-3 supplementation did not reduce frailty level or incidence. 3 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The ADL benefits in AD patients treated with donepezil were associated with less caregiving time and lower levels of caregiver stress. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This is the first study to show that WM integrity is associated with frailty in older adults. 3 key findings →
Design: cross-sectional Participants: 227 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
One hundred two (37.9%) participants were amyloid positive. 3 key findings →
Design: randomized controlled trial Participants: 269 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Milacemide does not appear to be an effective treatment in enhancing cognition in SDAT patients. 2 key findings →
Participants: 113 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The mean age of 35,570 new users of cholinesterase inhibitors (30,174 users of donepezil, 1,176 users of galantamine, 4,220 users of rivastigmine) was 82; 75% were women, and 82% were white. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Healthcare providers identified caregivers in most of the sample, but less than 50% assessed their well-being and needs. 2 key findings →
Design: randomized controlled trial Participants: 211 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
L-deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. 2 key findings →
Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Improving quality and delivery of care for people with Alzheimer disease and related dementias (ADRD) requires a comprehensive research agenda that encompasses the entire care continuum. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
L-deprenyl did not have a measurable impact on behavior or cognitive function over a 2-month period in this group of subjects with mild DAT. 1 key finding →
Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) affects more than 5 million Americans, with substantial consequences for individuals with AD, families, and society in terms of morbidity, mortality, and healthcare costs. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated